Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2023-08-17 Regulatory Filings
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding the approval of a Phase 3 clinical trial (IND) for their gout treatment, epaminurad, by the Taiwan Food and Drug Administration (TFDA). This is a standard 'Major Management Matter' disclosure (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a formal regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2023-08-17 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for JW Pharmaceutical, covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial statements, management discussion and analysis, and corporate governance information. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2023
2023-08-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (영업(잠정)실적) from JW Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the second quarter of 2023 compared to previous periods. As it is an initial announcement of quarterly financial results containing key highlights rather than a full comprehensive report, it falls under the 'Earnings Release' category. H1 2023
2023-08-09 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding their 'Compliance Program' (CP) status, which is a standard corporate governance disclosure in the Korean market. It details the operational performance and future plans for their internal compliance and ethics programs. Since it does not fit into specific categories like financial reports, M&A, or shareholder meetings, and is a formal regulatory disclosure filed with the exchange (KRX), it is classified as a Regulatory Filing (RNS).
2023-08-09 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding a clinical trial application (IND) for a gout treatment (epaminurad) in Singapore. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filings on the Korea Exchange (KRX). Since it is a specific regulatory announcement regarding business operations and clinical trial status that does not fit into the other specialized categories like M&A or financial reports, it is classified as a general regulatory filing.
2023-07-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and major contracts (such as collateral agreements) of a major shareholder (JW Holdings) in JW Shinyak. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-06-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.